

Figure W1. Structure of BV6. The structure of BV6 is shown according to Varfolomeev et al. [10].



Figure W2. Dose-response and kinetic analysis. Panc1 (left panels) and MiaPaCa2 (right panels) cells were treated with indicated concentrations of BV6 for 72 hours (A) or with indicated concentrations of gemcitabine in the presence (black bars) or absence (white bars) of 2 μM BV6 for 24 hours (B). Cell viability was assessed by MTT assay and is calculated as percentage of untreated cells. Means ± SEM of three independent experiments performed in triplicate are shown.



Figure W3. Effect of BV6 on expression of IAP proteins. Panc1 (upper panel) and MiaPaCa2 (lower panel) cells were treated with 100 nM (Panc1) or 66 nM (MiaPaCa2) gemcitabine and/or 2 μM BV6 for indicated time points. The expression of cIAP1, cIAP2, and XIAP was assessed by Western blot analysis. GAPDH served as loading control. One representative Western blot of two independent experiments is shown.



Figure W4. Effect of BV6 on the cell cycle. Panc1 cells were treated with 2 μM BV6 and/or 100 nM gemcitabine for 72 hours. Cell cycle profiles were assessed by propidium iodide staining of permeabilized cells and flow cytometry gating on alive cells. Percentages of cells in G_1, G_2/M, and S phases of the cell cycle are shown as mean ± SEM of three independent experiments.



Figure W5. BV6- and gemcitabine-induced NF-κB activation. Panc1 cells were treated for 1 hour with 10 ng/ml TNFα. NF-κB activation was determined by EMSA. (A) Nuclear protein extracts prepared from unstimulated or TNFα-stimulated cells were incubated with labeled NF-κB oligonucleotides presenting consensus NF-κB sequence (NF-κB) or mutated NF-κB sequence (MutNF-κB). (B) Cold competition of EMSA assay was performed using an excess (250 fmol) of unlabeled NF-κB oligonucleotides (NF-κB cold).



Figure W6. Effect of IκBα-SR on BV6- and gemcitabine-induced NF-κB activation. Panc1 cells stably transduced with a vector containing IκBα-SR (IκBα-SR) or empty vector control (Co) were treated for 4 hours with 2 μM BV6 and/or 100 nM gemcitabine or for 1 hour with 10 ng/ml TNFα. NF-κB activation was determined by EMSA.